Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... myeloid leukemia with 20% to 30% bone marrow blasts . METHODS: This secondary analysis of the AZA-001 phase 3 study ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. The search for better prognostic models in myelodysplastic syndromes.

    ... to acute myeloid leukemia based on the percentage of blasts , karyotype, and number of cytopenias, but the IPSS has several ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... three patients who relapsed on monotherapy with excess blasts at 12, 19, and 24 months, in whom lenalidomide was then resumed in ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. An update on the treatment of myelodysplastic syndromes.

    ... abnormalities, and the presence of bone marrow blasts . The only potentially curative treatment for MDS is hematopoietic ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocitic leukaemia ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.

    ... (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and ...

    Research Article last updated 06/20/2013 - 11:02am.

  7. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

    ... high-risk refractory anemia with excess blasts (RAEB) stages of MDS, the GMP population is increased in frequency ...

    Research Article last updated 03/05/2013 - 9:20am.

  8. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.

    ... , those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... At diagnosis, 126 patients (77%) had an excess of marrow blasts , and 95 patients (58%) had intermediate-2 or high-risk MDS according ...

    Research Article last updated 11/05/2012 - 8:57am.

  10. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

    ... of refractory anemia with excess blasts (RAEB)-1 were independent prognostic factors for AML progression ...

    Research Article last updated 03/05/2013 - 9:29am.